

The removal of uremic toxins

ANNEMIEKE DHONDT, RAYMOND VANHOLDER, WIM VAN BIESEN, and NORBERT LAMEIRE

Renal Division, Department of Medicine, University Hospital of Gent, Gent, Belgium

The removal of uremic toxins. Three major groups of uremic solutes can be characterized: the small water-soluble compounds, the middle molecules, and the protein-bound compounds. Whereas small water-soluble compounds are quite easily removed by conventional hemodialysis, this is not the case for many other molecules with different physicochemical characteristics. Continuous ambulatory peritoneal dialysis (CAPD) is often characterized by better removal of those compounds. Urea and creatinine are small water-soluble compounds and the most current markers of retention and removal, but they do not exert much toxicity. This is also the case for many other small water-soluble compounds. Removal pattern by dialysis of urea and creatinine is markedly different from that of many other uremic solutes with proven toxicity. Whereas middle molecules are removed better by dialyzers containing membranes with a larger pore size, it is not clear whether this removal is sufficient to prevent the related complications. Larger pore size has virtually no effect on the removal of protein-bound toxins. Therefore, at present, the current dialytic methods do not offer many possibilities to remove protein-bound compounds. Nutritional and environmental factors as well as the residual renal function may influence the concentration of uremic toxins in the body fluids.

Uremic syndrome can be defined as the deterioration of many biochemical and physiological functions, in parallel with the progression of renal failure [1]. This article summarizes the present state of knowledge of the biochemical, physiologic, and/or clinical impact of the most prevalent uremic retention solutes, divided according to their physicochemical characteristics: small water-soluble compounds, larger (middle) molecules, and protein-bound compounds. This analysis is followed by remarks about their specific intradialytic behavior, as summarized in Table 1. For each item, groups of solutes are first discussed, followed by a discussion of individual substances. Finally, the dialytic removal of these compounds, the ways to optimize this effort, and alternative options that could lead to a decrease of their serum levels will be examined.

Key words: hemodialysis, peritoneal dialysis, CAPD, dialysis efficiency, body fluid toxicity, renal disease.

© 2000 by the International Society of Nephrology

SMALL WATER-SOLUBLE COMPOUNDS

Guanidines

The guanidines are structural metabolites of arginine and urea. They cause several pathophysiologic alterations, such as inhibition of neutrophil superoxide production (abstract; Hiravama et al, *J Am Soc Nephrol* 8:238A, 1997), induction of seizures [2, 3], and suppression of natural killer cell response to interleukin-2 [4].

Arginine is the substrate of nitric oxide (NO) production. Some of the other guanidines, as arginine analogues, are strong competitive inhibitors of NO synthase, resulting in vasoconstriction [5, 6], hypertension [7], ischemic glomerular injury [8], immune dysfunction [9], and neurological changes [10].

Dialytic removal of the individual guanidino compounds is characterized by a substantial variability that cannot be explained by their molecular weight or isoelectric point [11]. Protein binding, or more probably multi-compartmental distribution, plays a role in this kinetic behavior. Despite their approximately similar molecular weight as urea, the dialytic kinetics may be quite different for some of the guanidines.

Because of their specific characteristics, some guanidines (creatinine and asymmetric N^GN^G dimethylarginine) are discussed separately.

Asymmetric dimethylarginine

Asymmetric dimethylarginine (ADMA) is significantly increased in end-stage renal disease (ESRD) [12] and has been implicated in the development of hypertension [13–15]. In hemodialysis (HD) patients, predialysis plasma ADMA concentrations are sixfold higher than those in control subjects, whereas in peritoneal dialysis (PD)-treated patients, plasma ADMA levels are similar to those in control subjects [16]. The increase in symmetric dimethylarginine (SDMA) is, however, more pronounced, but this compound is biologically less active. ADMA is the most specific guanidine with inhibitory effects on NO synthesis. In the brain, ADMA causes vasoconstriction and inhibits acetylcholine-induced vasorelaxation [17].

In spite of its low molecular weight, removal by HD is only in the range of 20 to 30% [12].

Table 1. Uremic toxins: Characteristics and dialytic removal

Type	Hydrophobic	Protein bound	Dialytic removal parallel with urea
Small water-soluble molecules			
Guanidines	–	–	–
Purines	–	–	±
Oxalate	–	–	+
Phosphorus	–	–	–
Urea	–	–	–
Middle molecules			
Cystatin C, Clara cell protein, leptin	–	–	–
Advanced glycosylation end products	±	±	–
Oxidation products	±	±	–
Peptides (β-endorphin, methionine-enkephalin, β-lipotropin, GIP I, GIP II, DIP, adrenomedullin)	–	–	–
β ₂ -microglobulin	–	–	–
Parathyroid hormone	–	–	–
Protein bound compounds			
Indoles (indoxyl sulfate)	+	+	–
Carboxy-methyl-propyl-furanpropionic acid (CMPF)	+	+	–
Hippuric acid	±	+	–
P-cresol	+	+	–
Polyamines (spermine, spermidine, putrescine, cadaverine)	+	+	–

Creatinine

Creatinine, an end-product of muscle breakdown, is retained during the progression of renal failure and has been held responsible for only a few side effects, such as chloride channel blocking [2, 3] and the reduction of the contractility of cultured myocardial cells [18]. It is a precursor of methylguanidine [19]. Creatinine diffuses from red blood cells to plasma during transit of the blood through the dialyzer, hence, creatinine is mainly extracted from the plasma during dialysis [20].

Purines

The best known purines retained in uremia are uric acid, xanthine, hypoxanthine, and guanosine. Both xanthine and hypoxanthine induce vasoconstriction, inhibit platelet-induced vasorelaxation [21], and disturb the endothelial barrier [22]. The purines are involved in disturbances of calcitriol production and metabolism [23–25], and possibly could take part in the calcitriol resistance that has been observed in experimental renal failure and in the presence of uremic biological fluids [26, 27]. The immune response to calcitriol, as illustrated by the expression of the lipopolysaccharide receptor CD14 on the monocyte membrane, is blunted in the presence of uric acid, xanthine, and hypoxanthine [28].

In spite of a markedly diminished urinary secretion of uric acid in renal failure, the rise in plasma uric acid levels is only moderate, because of intestinal secretion [29]. Uric acid is a small water-soluble compound that is removed from the plasma by HD in a similar way as urea [30]. However, its removal from the intracellular compartment is less efficient [31]. Dialytic removal of xanthine and hypoxanthine shows no correlation with the removal of urea and creatinine [30].

Oxalate

Secondary oxalosis in ESRD patients not suffering from primary hyperoxaluria is characterized by deposition of calcium oxalate in myocardium, bone, articulations, skin, and blood vessels [32]. Nowadays, this occurs less frequently, provided there is no excessive intake of oxalate precursors (ascorbic acid) [33] or no inflammatory bowel disease [34].

Oxalate clearance by PD is only 8% of the normal renal clearance. As a result, plasma oxalate levels are higher in PD patients than in controls [35]. Since oxalate is a small water-soluble compound, removal by efficient modern HD is usually adequate enough to prevent intratissular deposition.

Phosphorus

A high level of organic phosphates is related to pruritus and hyperparathyroidism [36]. Phosphorus excess inhibits the production of calcitriol by 1α-hydroxylase [37]. At least in animals, phosphate restriction has an attenuating effect on the progression of renal failure. The results are less compelling in humans [38].

The blood phosphorus concentration is the result of protein catabolism and intake of protein or other phosphorus-rich dietary sources. Restriction of oral protein intake increases the risk of protein malnutrition [36], which can be avoided by the administration of oral phosphate binders [39]. Their effect, however, is often insufficient, especially in subjects with high phosphorus intake. New phosphate binders (for example, lanthanumcarbonate, polynuclear iron hydroxide, cross-linked poly-allylamine-hydrochloride, calcium hydroxy-methylbutyrate), which presumably will be more efficient, have recently been

developed. However, the results of large scale control trials should be awaited before a definite opinion can be proposed. Phosphate is easily removed by HD, but the clearance from the intracellular component is considerably less substantial [40]. Consequently, dialytic removal is not always predictable, and substantial postdialytic rebound may annihilate much of the intradialytic removal.

Urea

Despite extensive study, the number of reports in which an adverse impact of urea has been reported is low. Johnson et al demonstrated that dialysis against high urea dialysate worsens clinical symptoms, but globally, the differences were not impressive and not consistent in every patient [41]. This study was not controlled. Lim, Gasson, and Kaji have shown that urea inhibits NaK₂Cl cotransport [42], which is an ubiquitous process that maintains cell volume and influences extrarenal potassium regulation. The presence of urea in blood has been held responsible for a decreased affinity of oxygen for hemoglobin [43]. Urea inhibits macrophage inducible NO synthesis at the post-transcriptional level (abstract; Prabhakar et al, *J Am Soc Nephrol* 8:24A, 1997).

Urea is one of the only solutes that has been correlated with clinical outcome of HD [44]. Low reduction rates rather than high serum concentrations are related to increased mortality [45]. In this way, urea can be conceived as a marker of uremic toxin removal, rather than being a toxin itself.

However, one might question the validity and representativity of urea as a marker for the retention and even for the removal of other solutes. Even if dialytic removal from the plasma is identical, the shift from the intracellular compartment to the plasma might be different, as is the case for creatinine and uric acid [30, 31]. For various other solutes, for example, the protein-bound compounds [46] or the larger molecules in case of conventional low-flux dialysis, no or only a weak correlation between urea and these molecules can be expected.

LARGE (MIDDLE) MOLECULES

Middle molecules (molecular weight range of 300 to 12,000 D) have been held responsible for at least some aspects of the uremic syndrome: Chromatographic fractions between 1 and 5 kD extracted from human uremic ultrafiltrate inhibit appetite and suppress food intake in animals [47]. This effect was obtained only after concentration of the samples by a factor of 25. A 500 to 2000 D subfraction of uremic serum inhibits apolipoprotein (apo) A-I secretion [48]. Andress, Howard, and Birnbaum described an inhibitor of osteoblast mitogenesis originating from uremic plasma, with a molecular weight in the range between 750 and 900 D [49].

Dialysis membranes with a capacity to remove middle

molecules (high-flux membranes) have been related to lower morbidity and mortality of dialysis patients [50–53]; however, these highly efficient membranes at the same time are often less complement activating than their counterpart in many studies, which is usually unmodified cellulose. This might as well have an impact on clinical outcome.

Molecules with a molecular weight of more than 12 kD might display a comparable kinetic behavior. Serum concentrations of cystatin C (13.3 kD, a cysteine-proteinase inhibitor) and Clara cell protein (CC16; 15.8 kD, an immunosuppressive α -microprotein) [54] are elevated in renal failure. High-flux membranes remove up to 50% of cystatin C, whereas Clara cell protein is not eliminated by HD [54].

Leptin, a 16 kD plasma protein suppressing appetite [55], and inducing weight reduction in mice [56], is retained in renal failure [57]. Leptin levels in uremia are positively correlated to body fat [58]. Therefore, the biochemical role of leptin in renal failure remains inadequately defined.

Leptin is not removed by conventional HD with modified cellulose [57]. In contrast, dialysis with high-flux membranes lowers leptin levels [59].

Several other uremic solutes conform with the definition of middle molecules [parathyroid hormone (PTH), β_2 -microglobulin (β_2m), peptides, advanced glycosylation end product (AGEs)] and are discussed separately in what follows.

Advanced glycosylation end products

Glucose and other reducing sugars react nonenzymatically with free amino groups to form stable Amadori products. Through a series of chemical rearrangements, some Amadori products are converted to AGEs [60]. Several of the AGEs in ESRD are peptide-linked degradation products (molecular weight, 2000 to 6000 D) [61], which show strong cross-linking activity with long-living body proteins.

Advanced glycosylation end products are involved in modification of tissue structures and in functional alterations of enzymes. AGEs induce inflammatory reaction by monocytes [62]. AGE-modified β_2m may play a role in the formation of dialysis-associated amyloidosis [63]. Protein-bound AGEs can react with and chemically inactivate NO [64], a potent endothelium-derived vasodilator, anti-aggregant, and antiproliferative factor. AGEs may also be related to oxidative protein modification [65]. Their accumulation was recently attributed to increased plasma concentrations of small reactive carbonyl precursors resulting from increased oxidation of carbohydrates and lipids or inadequate inactivation of these compounds [66].

Removal of AGEs by conventional HD is ineffective. Elimination is significantly higher with high-flux dialysis [67]; however, despite this more efficient removal, levels remain still far above normal [67].

Oxidation products

Enhanced oxidative capacity in uremia results in structural modification and irreparable damage, with albumin and low-density lipoprotein (LDL) being its major targets [65, 68, 69]. Oxidized LDL is claimed to play a role in atherogenesis [70]. Several smaller molecular compounds might also result from oxidation [71]. Organic chloramines originate from the chemical binding of hypochlorite moieties, produced after leukocyte activation, to retained organic compounds [65]. They increase endothelial permeability [72] and affect liver function and hepatic perfusion pressure [73].

Peptides

The opioid peptides β -endorphin, methionine-enkephalin, and β -lipotropin are elevated in dialyzed patients [74], and opioids influence the endocrine function and vasopressor response. Granulocyte-inhibiting protein I (GIP I) affects various functions of the polymorphonuclear cell and shows structural analogies with the κ light chains [75]. Another peptide with granulocyte-inhibitory effect (GIP II) has partial homology with β_2 m [76]. A degranulation-inhibiting protein (DIP), identical to angiogenin, was isolated from plasma ultrafiltrate [77]. A variant of ubiquitin inhibits polymorphonuclear chemotaxis [78]. Adrenomedullin, a 52-amino acid hypotensive peptide, activates inducible NO synthase [79].

Most peptides are larger molecules that are supposed to have multicompartamental behavior during dialysis. They are only removed by dialyzers with a large pore size or are not removed at all. Even if removal is present, plasma levels far above normal are reached.

β_2 -microglobulin

β_2 -microglobulin (molecular weight of about 12,000 D) is a component of the major histocompatibility antigen. Dialysis-related amyloid, as found in amyloid bone disease and carpal tunnel syndrome after long-term dialysis, is to a large extent composed of β_2 m. This amyloidosis sometimes develops as early as one to two years following the start of dialysis [80, 81].

Advanced glycosylation end products (discussed previously in this article) and β_2 m are closely connected. AGE-modified β_2 m has been identified in amyloid of hemodialyzed patients [82]. AGE-modified β_2 m enhances monocytic migration and cytokine secretion [63], suggesting that foci containing AGE- β_2 m may initiate an inflammatory reaction, leading to bone/joint destruction. On the other hand, AGE modification is not essential for β_2 m-related tissue destruction (abstract; Bailey and Moe, *J Am Soc Nephrol* 8:227A, 1997). β_2 m amyloidosis is not more prevalent in diabetic renal failure patients, although AGE modification in these patients should be substantial [83].

Cuprophane membranes do not remove β_2 m, whereas large-pore membranes do. Some of the large-pore dialyzer membranes, such as polyacrylonitrile, adsorb substantial amounts of β_2 m [84]. It has been suggested that the use of these high permeability membranes lessens the likelihood for development of dialysis amyloidosis [85].

Complement factor D

Complement factor D accumulates because of a decrease in its renal removal [86–88]. Its protease activity is highly specific for its natural substrate, complement factor B. An increased level of complement factor D activates the alternative pathway of complement [89], which could, in part, be responsible for the inflammatory status in chronic renal disease. Some dialysis membranes (for example, AN69) adsorb complement factor D [86].

Parathyroid hormone

Parathyroid hormone (PTH), a middle molecule with a molecular weight of ± 9000 D, is generally recognized as a major uremic toxin, although its increased level during ESRD is merely attributable to enhanced glandular secretion, rather than to decreased removal by the kidneys. Excess PTH gives rise to an increase in intracellular calcium, resulting in disturbances in the function of virtually every organ system [90–94]. Hyperparathyroidism is also related to uremic pruritus.

The increased PTH concentration in uremia is the consequence of a number of compensatory homeostatic reactions in response to phosphate retention, decreased production of calcitriol [$1,25(\text{OH})_2$ vitamin D_3] and/or hypocalcemia.

During HD, PTH concentrations are mainly dependent on intradialytic changes of ionized calcium; in addition, dialysis membranes with a large pore size remove PTH. Differences in plasma concentrations at the end of the dialysis session are subtle, however, and can be expected to be compensated by homeostatic adaptations in glandular secretion [95].

PROTEIN-BOUND COMPOUNDS

The molecular structure of some of the most important protein-bound uremic toxins are illustrated in Figure 1, together with their molecular weight and protein binding. Figure 2 illustrates their specific elution pattern during high-performance liquid chromatography (HPLC), with a gradient from hydrophilic to lipophilic. As they all elute in the lipophilic range, there seems to be a relationship between protein binding and lipophilicity.

Indoles

Indoles are found in various plants and are produced by the intestinal flora. Indoxyl sulfate (discussed later in this article), tryptophan, melatonin, and indole-3-acetic





Chemical structure	Compound name	Molecular weight	Percent protein binding
	Indoxyl sulfate	251	89
	Hippuric acid	179	41
	P-cresol	108	88
	CMPF	240	100

Fig. 1. Protein-bound uremic toxins: Chemical formula, molecular weight, and percent protein binding.




Fig. 2. Elution pattern of uremic ultrafiltrate with HPLC. The elution pattern is such that the gradient goes from hydrophilic (left on the chromatogram) to hydrophobic (right). Identified protein-bound uremic solutes: a, indoxyl sulfate; b, tryptophan; c, hippuric acid; d, indole-3-acetic acid; e, CMPF; f, internal standard.

acid all are indoles; however, the concentrations of tryptophan and melatonin are not increased in uremia. Some indoles are carcinogens [96], whereas others are tumor growth inhibitors [97]. As a protein-bound compound, indole-3-acetic acid enhances drug toxicity by competition for drug protein binding and inhibition of tubular secretion [98].

Removal of the protein-bound compounds during HD is only limited and is not enhanced during treatment with high-flux membranes (Fig. 3) [46].

3-Carboxy-4-methyl-5-propyl-2-furanpropionic acid

3-Carboxy-4-methyl-5-propyl-2-furanpropionic acid (CMPF) is a strongly lipophilic uremic solute and one

of the major inhibitors of drug protein binding [98]. It causes a decrease in renal excretion of various compounds, which are removed via the para-aminohippuric acid (PAH) pathway. CMPF inhibits hepatic glutathione-S-transferase [99], deiodination of T4 by cultured hepatocytes [100], and ADP-stimulated oxidation of NADH-linked substrates in isolated mitochondria [101]. Because CMPF is strongly bound to albumin, its removability during HD is hampered. Even high-flux dialysis removes no CMPF [46, 101]. This is illustrated in Figure 3. In contrast, predialysis plasma concentrations of CMPF decrease significantly when albumin-permeable membranes are used [102, 103]. Also, in continuous ambulatory PD (CAPD), a significant amount of albumin is




Fig. 3. Percentage change in serum concentrations of uremic toxins after correction for hemoconcentration during dialysis with low-flux polysulfone (A), high-flux polysulfone (B), and high-flux cellulose triacetate (C). Symbols are: ■, creatinine; □, urea; ▨, indoxyl sulfate; ◻, p-cresol; ▩, CMPF. High flux polysulfone or high-flux cellulose triacetate vs. low-flux polysulfone. Symbols are: NS, not significant; •, $P < 0.05$ vs. urea; ••, $P < 0.01$ vs. urea; *, $P < 0.05$ vs. creatinine; **, $P < 0.01$ vs. creatinine.

lost into the dialysate. Hence, in CAPD patients, CMPF levels are more than three times lower than in HD patients, pointing to a better removal by CAPD [104]; however, this may also be the consequence of a higher residual renal function than in HD.

Hippuric acid

Environmental or toxicologic contact with toluene is a source of hippuric acid [105]. Toluene is transformed to benzyl alcohol, benzoic acid, and after glycation, to hippuric acid. Benzoic acid is also widely used as a food preservative and is a product of phenylalanine metabolism.

Hippuric acid, as a protein-bound compound, may enhance toxicity of protein-bound drugs and uremic solutes by competition for protein binding [106, 107] and interference with tubular organic acid secretion [98]. Hippuric acid has been related to insulin resistance and glucose intolerance [108]. Hippuric acid is easily removed by HD, with a 60% decrease of the free fraction [109]. However, because of its protein binding, during HD hippuric acid behaves like a larger molecule [110]. The removal of hippuric acid is more pronounced by hemodiafiltration compared with HD [31].

Homocysteine

Homocysteine (Hcy) is a sulfur-containing amino acid that is produced by the demethylation of methionine. Its retention results in the cellular accumulation of S-adenosyl Hcy (AdoHcy), an extremely toxic compound that inhibits methyltransferases [111]. Moderate hyperhomocysteinemia is an independent risk factor for cardiovascular disease [112, 113].

Patients with chronic renal failure have total serum Hcy levels that are twofold to fourfold above normal. The serum concentration depends not only on the degree of kidney failure, but also on nutritional intake (methionine), vitamin status (folate), genetic factors, and renal metabolism [114–117].

Hcy increases the proliferation of vascular smooth muscle cells, one of the most prominent hallmarks of atherosclerosis [118]. Hcy also disrupts several vessel wall-related anticoagulant functions, resulting in enhanced thrombogenicity [119].

Hcy levels can be reduced by folic acid, vitamin B₆, and/or vitamin B₁₂ administration [120, 121]. The ESRD population may require higher quantities of vitamins than the nonuremic population [122]. To our knowledge, direct clinical proof of the benefit of such a treatment in uremia is not available.

Homocysteine is partly bound to albumin so that removal by HD is hindered [123].

Indoxyl sulfate

Indoxyl sulfate is metabolized by the liver from indole, which is produced by the intestinal flora as a metabolite of tryptophan. As a strongly protein-bound organic compound, it enhances drug toxicity by competition with acidic drugs at the protein-binding sites [106] and inhibits the active tubular secretion of the same compounds [98]. Indoxyl sulfate inhibits deiodination of T₄ [100]. The oral administration of indole or of indoxyl sulfate to uremic rats causes a progressive deterioration of renal function and an enhancement of glomerular sclerosis [124]. Removal by dialysis is reduced because of protein binding (Fig. 3). Alternative removal procedures such as intestinal adsorption or hemoperfusion should be considered.

P-cresol

P-cresol is a phenolic, volatile compound with a molecular weight of 108.1 D. It is produced by intestinal bacteria, as a result of the metabolism of tyrosine and phenylalanine [125]. Environmental sources are toluene, cigarette smoke, and menthofuran, which is present in several herbal medicines, flavoring agents, and psychedelic drugs [126].

P-cresol is strongly toxic for hepatocytes, inducing LDH leakage from rat liver slices [127], and inhibits various metabolic processes related to the production of active free radicals by phagocytic leukocytes [128]. Both hepatocyte aluminum uptake and the toxic effect of aluminum on hepatocytes are increased [129].

Prevention of the intestinal absorption of p-cresol by administration of oral sorbents decreases its serum concentration in rats [130]. Removal by HD is markedly

lower than for urea and creatinine [131] because of the lipophilicity and its protein binding (Fig. 3).

Polyamines

The best known polyamines (spermine, spermidine, putrescine, and cadaverine) have a high affinity for cells and proteins and inhibit erythroid colony growth in a dose-dependent way [132]. Several polyamines interact with the N-methyl-D-aspartate (NMDA) receptor [133], which plays a role in channel conductance and Ca^{++} permeability of brain cells. Spermine also reduces intracellular free calcium in permeabilized pancreatic islets [134] and inhibits NO synthase [135].

One of the problems with the polyamines is the relative impermeability of the cell membrane for these compounds. Their preferential intracellular storage and protein binding results in a multicompartmental behavior and a deceptively low removal during dialysis.

OBJECTIVATION AND OPTIMALIZATION OF HEMODIALYTIC REMOVAL OF UREMIC TOXINS

Obviously, small solutes with urea as marker molecule are not the main and certainly not the only culprits of uremic toxicity. Nevertheless, urea is used as a standard to describe delivered dose of dialysis. $\text{Kt/V}_{\text{urea}}$, as well as urea reduction rate (URR), is generally used for that purpose. Urea can easily be determined in blood, and evidence is found in the literature that increasing $\text{Kt/V}_{\text{urea}}$ and/or URR is associated with a better outcome both for morbidity and mortality. Held et al, for example, demonstrated that a 0.1 increase in Kt/V resulted in a 7% reduction in mortality [136].

Since the introduction of the Kt/V concept in 1985 [137], several methods have been developed to measure Kt/V , from single pool to multicompartmental, from measurements on the bloodside to measurements on spent dialysate, and from postdialysis urea values determined immediately after dialysis to urea measurements after a 30-minute equilibration time.

Multicompartment models have been introduced because of the slow movement of solutes from the tissues to the blood compartment, resulting in solute disequilibrium. This delayed equilibration is responsible for a reduced dialysis efficiency since solutes withheld in tissues are not dialysable.

Only a limited number of factors can be influenced to increase HD efficiency: time of dialysis treatment, blood flow, dialysate flow, ultrafiltration rate, membrane characteristics such as surface of dialyzer, diffusion, adsorption, and convection capacity. Increasing blood flow leads to an enhanced clearance of small solutes, but can induce hemolysis. Above a certain threshold, increases in clearance are relatively disappointing. Increasing dialysate flow above 500 mL/min is useful if high blood flows

are applied. The larger the surface area of the dialyzer membrane, the larger the expected clearances will be. However, the drawback of large surface membranes is the increased bioincompatibility [138]. The duration of dialysis is one of the most problematic variables in dialysis efficiency. Increasing dialysis time asks efforts from both the dialysis center and the patient. Barriers to increase time are multiple in nature.

Organization of the dialysis center. When three sessions daily have to be performed on the same monitor, the duration of one session can hardly exceed four hours.

Organization of patient transport. Dialysis patients share common transportation, even with patients dialyzed in different centers; hence dialysis schedules need to be tailored to one another.

Lack of motivation of the patient. Most patients do not want to dialyze for more than four hours because they are not convinced that the efforts and discomfort of a longer dialysis are compensated by a better outcome. A promising alternative is overnight dialysis over six to eight hours, resulting in a better removal of toxins and water, even with lower blood and dialysate flows than conventionally applied.

One of the major disadvantages of Kt/V urea is the fact that it reflects only on urea. As previously stated, uremic toxicity is not only or not at all mediated by urea accumulation. Furthermore, the removal patterns of other potential uremic solutes are different from those of urea; for example, the use of high-flux membranes increases the removal of middle molecules, AGEs or $\beta_2\text{m}$, but not of urea. Therefore, to quantitate efficiency of high-flux dialysis, a marker for middle molecules and/or protein bound should be found: The marker, whether or not with clinical relevance, should be easy to measure. For that purpose, Leyboldt et al measured the vitamin B_{12} clearance [139].

Besides the uremic toxins with large molecular weight, toxins can have an impaired removal because of pronounced protein binding. An alternative method that enables the dialyzability of protein-bound toxins from plasma is the use of a high-flux membrane in combination with an albumin-enriched dialysate [140]. For lipid-soluble toxins, even a liposome-enriched dialysate has been proposed. These are, however, labor intensive and expensive strategies. Alternatively, adsorptive systems removing protein-bound or lipophilic uremic toxins might be considered.

REMOVAL OF UREMIC TOXINS BY PERITONEAL DIALYSIS

Removal of toxins by PD differs in many aspects from that by HD, the most important difference being the CAPD and continuous cycling PD (CCPD) or nearly continuous [nightly intermittent PD (NIPD)] nature of




Fig. 4. Weekly BUN profiles for hemodialysis and CAPD.

the treatment, the lower efficiency per unit of time, and the use of a “personalized” membrane that is unique for every patient.

The continuous nature of the treatment results in a stable plasma concentration of uremic toxins, and this in contrast with the sawtooth pattern seen in HD, as illustrated in Figure 4. It is based on this difference that Keshaviah, Nolph, and Van Stone, using the peak concentration hypothesis, explained why CAPD patients suffer a minor degree of uremic toxicity at Kt/V values being associated with overt uremic complaints in HD patients [141]. The peak concentration hypothesis states that not the time-averaged urea, but rather the peak concentrations of urea are responsible for toxicity. When a PD and a HD patient have the same time-averaged concentration of urea during one week, the urea levels in the HD patient will, because of the intermittent nature of the treatment, be above that average for half of the week. Therefore, HD patients need lower time-averaged urea concentrations in order to maintain their urea levels at peak heights lower than those of PD patients. For the same reason, Kt/V levels in patients on NIPD must be somewhat higher than in CAPD patients.

The continuous nature of PD also makes the application of “urea kinetics” to describe the adequacy of PD not only somewhat contradictory, but also complicated. Indeed, the determination of the distribution volume “ V ” cannot be calculated from the urea kinetics between dialysis sessions. A more elegant approach would be to use the “urea removal index,” as suggested by Chen et al [142]. These authors calculated the total mass of urea removed by dialysis. They found that this removal index was the same in HD and PD patients, and this despite differences in Kt/V .

Apart from kinetic explanations for the similar outcome between HD and PD despite a lower amount of urea removal for PD, another hypothesis could be that urea by itself is not toxic, whereas its removal is not representative for those compounds with proven toxicity, such as the middle molecules and the protein-bound compounds.

Compared with a conventional artificial membrane, it appears that an average peritoneal membrane has fewer pores, but with a greater radius [143, 144]. This implicates that the removal of middle molecules will be higher in PD compared with HD. Consequently, in patients on PD with a comparable weekly removal of small uremic toxins as HD patients, the removal of middle molecules will be superior. As the removal of middle molecules is independently associated with mortality risk [145], this higher removal may explain the better survival of patients on PD, at least in the first three to four years after start of renal replacement therapy [145, 146]. After this period, residual renal function has deteriorated in most cases, often resulting in an inadequate clearance for both small and middle molecules, explaining the increased mortality [147]. Also, protein-bound molecules are lower in the serum of PD patients, either because of better removal or higher residual renal function [148].

The better removal of protein-bound molecules might also explain the slower decline in residual renal function in PD patients. Motojima et al demonstrated that in subtotally nephrectomized rats treated with PD for 12 weeks, the glomerular filtration rate was higher compared with controls, whereas the progression of glomerular sclerosis, evaluated with light microscopy, was attenuated [149]. Niwa, Ise, and Miyazaki demonstrated that this kind of glomerulosclerosis could be stimulated by

the administration to uremic rats of indole, a precursor of the uremic toxin indoxyl sulfate [150]. Intestinal binding of these compounds or their precursors by AST120 could prevent progression of renal failure. The observation of Motojima et al and the better preservation of residual renal function in PD patients could thus possibly be attributed to the removal of this kind of substances. Also, the higher hematocrits and the lower need for erythropoietin in PD patients [151, 152] could be partially attributed to the better removal of some uremic toxins. Substances like polyamines and CMPF have been identified as possible inhibitors of erythropoiesis, which are removed by PD but not by conventional HD [148, 153].

NONDIALYTIC FACTORS AFFECTING UREMIC SOLUTE CONCENTRATION

Nutritional and environmental effects

Several environmental sources in the generation of uremic toxins too often have been disregarded. These sources include: (1) the presence in food of conservation agents, trace elements, AGEs and other precursors, apart from the traditionally considered protein intake; (2) the contact with volatile compounds such as toluene; (3) herbal medicines, quack remedies, and psychedelic drugs; and (4) environmental noxes imposed by dialysis, because of the leaching from plastic devices or dialysate. An additional problem could be that the contact risks are different for each individual; if specific toxins play a role in each specific individual, they may go unrecognized in the case mix of large random populations.

Several toxins are produced from protein breakdown or from metabolization of amino acids. Therefore, protein restriction could decrease toxicity were it not that protein malnutrition might by itself increase morbidity and mortality [45].

Most solutes with toxic capacity or their precursors enter the body through the gastrointestinal tract. Some of them are produced by the intestinal flora. Inhibition of intestinal absorption and modifications in the composition of the intestinal flora could influence solute retention [130, 154, 155]. A specific oral sorbent (AST120) has been demonstrated to decrease indoxyl sulfate and p-cresol in serum of uremic rats [124, 130, 156, 157]. Other oral binders already in use today are several potassium and phosphate binders. Some of these compounds may exert their own toxicity, as is the case for the aluminum salts. In general, the possibilities to decrease intestinal delivery of uremic solutes have been insufficiently exploited.

Biological interaction between compounds

Until now, mainly the toxic action of single solutes has been emphasized, without considering the interference between compounds. Some of the uremic solutes inter-

fere with functions that directly affect the toxic action of other solutes. The uremic milieu decreases the expression of PTH receptors and hence the cellular response to PTH [158, 159]. On the other hand, uremic solutes also blunt the response to 1,25-(OH)₂vitamin D₃ and hence might increase the production of PTH [27]. As a consequence of the inhibition of enzymatic actions, metabolization and breakdown of toxic solutes may be altered or hindered. The kidneys per se play an important role in the metabolization of solutes; when renal mass is lost, these metabolic processes are also restricted.

Most uremic patients are prescribed a host of drugs. The influence of drugs on uremic toxicity can be attributed to either interference of drugs with protein binding and/or tubular secretion of uremic toxins or the production of metabolites, which are not excreted by the failing kidneys, exerting their own toxicity.

Medication may also interfere at the functional level. For example, angiotensin-converting enzyme inhibitors might decrease the sensibility of erythrocyte progenitors to erythropoietin [160]. On the other hand, drugs may be of help to reduce toxin concentrations. Allopurinol decreases uric acid. Rhubarb tannins decrease the concentration of urea, creatinine, guanidino-succinic acid, and methylguanidine in rats with acute renal failure [161]. Biotin administration results in an improvement of uremic neuropathy [162]. Vitamin C increases urinary CMPF excretion but does not alter plasma concentration in hemodialyzed patients [103]. Hcy in uremic patients can be lowered by supplementation of folic acid, a compound favoring remethylation of Hcy to methionine [122, 163].

Residual renal function

The impact of residual renal function on uremic retention should not be neglected. One should realize that adding a creatinine clearance of 5 mL/min to the clearance imposed by dialysis means an increase in creatinine removal by ± 50 to 100% [44]. This relative contribution is even more important for larger molecules and molecules with multicompartamental behavior, which are removed less efficiently by dialysis procedures. Therefore, the longer preservation of residual renal function with CAPD, compared with conventional HD, may be important. Uremic retention solutes have also been held responsible for deterioration of renal function, and at least one of these compounds, indoxyl sulfate, is better removed in CAPD patients [124].

*Reprint requests to Annemieke Dhondt, M.D., Ph.D., Renal Division, University Hospital, De Pintelaan 185, 9000 Gent, Belgium.
E-mail: Annemie.Dhondt@rug.ac.be*

REFERENCES

1. VANHOLDER R, DE SMET R, HSU C, VOGELEERE P, RINGOIR S: Uremic toxins: The middle molecule hypothesis revisited. *Semin Nephrol* 14:205-218, 1994

2. DE DEYN PP, MACDONALD RL: Guanidino compounds that are increased in uremia inhibit GABA and glycine responses on mouse neurons in cell culture. *Ann Neurol* 28:627-633, 1990
3. D'HOOGHE R, PEI YQ, MARESCAU B, DE DEYN PP: Convulsive action and toxicity of uremic guanidino compounds: Behavioral assessment and relation to brain concentration in adult mice. *J Neurol Sci* 112:96-105, 1992
4. ASAKA M, IIDA H, IZUMINO K, SASAYAMA S: Depressed natural killer cell activity in uremia. *Nephron* 49:291-295, 1988
5. MACALLISTER RJ, WHITLEY G, VALLANCE P: Effects of guanidino and uremic compounds on nitric oxide pathways. *Kidney Int* 45:737-742, 1994
6. WHITE R, BAREFIELD D, RAM S, WORK J: Peritoneal dialysis solutions reverse the hemodynamic effects of nitric oxide synthesis inhibitors. *Kidney Int* 48:1986-1993, 1995
7. REES DD, PALMER RM, MONCADA S: Role of endothelium-derived nitric oxide in the regulation of blood pressure. *Proc Natl Acad Sci USA* 86:3375-3378, 1989
8. BAYLIS C, MITRUKA B, DENG A: Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. *J Clin Invest* 90:278-281, 1992
9. LIEW FY, MILLOTT S, PARKINSON C, PALMER RM, MONCADA S: Macrophage killing of Leishmania parasite *in vivo* is mediated by nitric oxide from L-arginine. *J Immunol* 144:4794-4797, 1990
10. JOHNS RA, MOSCICKI JC, DIFAZIO CA: Nitric oxide synthase inhibitor dose-dependently and reversibly reduces the threshold for halothane anesthesia: A role for nitric oxide in mediating consciousness? *Anesthesiology* 77:779-784, 1992
11. DE DEYN PP, ROBITAILLE P, VANASSE M, QURESHI IA, MARESCAU B: Serum guanidino compound levels in uremic pediatric patients treated with hemodialysis or continuous cycle peritoneal dialysis. *Nephron* 69:411-417, 1995
12. MACALLISTER RJ, RAMBAUSEK MH, VALLANCE P, WILLIAMS D, HOFFMANN KH, RITZ E: Concentration of dimethyl-L-arginine in the plasma of patients with end-stage renal failure. *Nephrol Dial Transplant* 11:2449-2452, 1997
13. ANDERSTAM B, KATZARSKI K, BERGSTRÖM J: Serum levels of NG, NG-dimethyl-L-arginine, a potential endogenous nitric oxide inhibitor in dialysis patients. *J Am Soc Nephrol* 8:1437-1442, 1997
14. GOONASEKERA CD, REES DD, WOOLARD P, FRENCH A, SHAH V, DILLON MJ: Nitric oxide synthase inhibitors and hypertension in children and adolescents. *J Hypertension* 15:901-909, 1997
15. MATSUOKA H, ITOH S, KIMOTO M, KOHNO K, TAMAI O, WADA Y, YASUKAWA H, IWAMI G, OKUDA S, IMAIZUMI T: Asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in experimental hypertension. *Hypertension* 29:242-247, 1997
16. KIELSTEIN J, BOGER R, BODE-BOGER S, SCHAFFER J, BARBEY M, KOCH K, FROLICH J: Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: Relationship to treatment method and atherosclerotic disease. *J Am Soc Nephrol* 10:594-600, 1999
17. FARACI FM, BRIAN JE, HEISTAD DD: Response of cerebral blood vessels to an endogenous inhibitor of nitric oxide synthase. *Am J Physiol* 269:H1522-H1527, 1995
18. WEISENSEE D, LÖW-FRIEDRICH I, RIEHLE M, BEREITER-HAHN J, SCHOEPPE W: In vitro approach to "uremic cardiomyopathy." *Nephron* 65:392-400, 1993
19. YOKOZAWA T, FUJITSUKA N, OURA H, AKAO T, KOBASHI K, IENAGA K, NAKAMURA K, HATTORI M: Purification of methylguanidino synthase from the rat kidney. *Nephron* 63:452-457, 1993
20. DESCOMBES E, PERRIARD F, FELLAY G: Diffusion kinetics of urea, creatinine and uric acid in blood during hemodialysis: Clinical implications. *Clin Nephrol* 40:286-295, 1993
21. YANG BC, KHAN S, MEHTA JL: Blockade of platelet-mediated relaxation in rat aortic rings exposed to xanthine-xanthine oxidase. *Am J Physiol* 266:H2212-H2219, 1994
22. BERMAN RS, MARTIN W: Arterial endothelial barrier dysfunction: Actions of homocysteine and the hypoxanthine-xanthine oxidase free radical generating system. *Br J Pharmacol* 108:920-926, 1993
23. HSU CH, PATEL SR, YOUNG EW, VANHOLDER R: Effect of purine derivatives on calcitriol metabolism in rats. *Am J Physiol* 260:F596-F601, 1991
24. HSU CH, VANHOLDER R, PATEL S, DE SMET R, SANDRA P, RINGOIR SMG: Subfractions of uremic plasma ultrafiltrate inhibit calcitriol metabolism. *Kidney Int* 40:868-873, 1991
25. VANHOLDER R, PATEL S, HSU CH: Effect of uric acid on plasma levels of 1,25(OH)₂D in renal failure. *J Am Soc Nephrol* 4:1035-1038, 1993
26. HSU CH, PATEL SR, YOUNG EW, VANHOLDER R: The biological action of calcitriol in renal failure. (Editorial Review) *Kidney Int* 46:605-612, 1994
27. PATEL SR, KE HQ, VANHOLDER R, KOENIG RJ, HSU CH: Inhibition of calcitriol receptor binding to vitamin D response elements by uremic toxins. *J Clin Invest* 96:50-59, 1995
28. GLORIEUX G, HSU C, VAN KAER J, VOGELEERE P, DE SMET R, LAMEIRE N, VANHOLDER R: Inhibition of calcitriol induced monocyte CD14-expression by uremic toxins: Role of purines. *J Am Soc Nephrol* 9:1826-1831, 1998
29. VAZIRI ND, FREEL RW, HATCH M: Effect of chronic experimental renal insufficiency on urate metabolism. *J Am Soc Nephrol* 6:1313-1317, 1995
30. VANHOLDER RC, DE SMET RV, RINGOIR SM: Assessment of urea and other uremic markers for quantification of dialysis adequacy. *Clin Chem* 38:1429-1436, 1992
31. LANGSDORF LJ, ZYDNEY AL: Effect of uremia on the membrane transport characteristics of red blood cells. *Blood* 81:820-827, 1993
32. SALYER WR, HUTCHINS GM: Cardiac lesions in secondary oxalosis. *Arch Intern Med* 134:250-252, 1974
33. ABUELO JG, SCHWARTZ ST, REGINATO AJ: Cutaneous oxalosis after long-term hemodialysis. *Arch Intern Med* 152:1517-1520, 1992
34. MARANGELLA M, VITALE C, PETRARULO M, COSSEDDU D, GALLO L, LINARI F: Pathogenesis of severe hyperoxalemia in Crohn's disease-related renal failure on maintenance haemodialysis: Successful management with pyridoxine. *Nephrol Dial Transplant* 7:960-964, 1992
35. MARANGELLA M, BAGNIS C, BRUNO M, PETRARULO M, GABELLA P, LINARI F: Determinants of oxalate balance in patients on chronic peritoneal dialysis. *Am J Kidney Dis* 21:419-426, 1993
36. COBURN JW, SALUSKY IB: Control of serum phosphorus in uremia. *N Engl J Med* 320:1140-1142, 1989
37. LLACH F: Secondary hyperparathyroidism in renal failure: The trade-off hypothesis revisited. *Am J Kidney Dis* 25:663-679, 1995
38. LOGHMAN-ADHAM M: Role of phosphate retention in the progression of renal failure. *J Lab Clin Med* 122:16-26, 1993
39. SCHILLER LR, SANTA ANA CA, SHEIKH MS, EMMETT M, FORDTRAN JS: Effect of the time of administration of calcium acetate on phosphorus binding. *N Engl J Med* 320:1110-1113, 1989
40. HEAF J, JENSEN S: Normalized cellular clearance of creatinine, urea and phosphate. *Nephron* 67:197-202, 1994
41. JOHNSON WJ, HAGGE WW, WAGONER RD, DINAPOLI RP, ROSEVEAR JW: Effects of urea loading in patients with far-advanced renal failure. *Mayo Clin Proc* 47:21-29, 1972
42. LIM J, GASSON C, KAJI DM: Urea inhibits NaK₂Cl cotransport in human erythrocytes. *J Clin Invest* 96:2126-2132, 1995
43. MONTI JP, BRUNET PJ, BERLAND YF, VANUXEM DC, VANUXEM PA, CREVAT AD: Opposite effects of urea on hemoglobin-oxygen affinity in anemia of chronic renal failure. *Kidney Int* 48:827-831, 1995
44. VANHOLDER RC, RINGOIR SM: Adequacy of dialysis: A critical analysis. (editorial review) *Kidney Int* 42:540-558, 1992
45. OWEN WF, LEW NL, LIU Y, LOWRIE EG, LAZARUS JM: The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. *N Engl J Med* 329:1001-1006, 1993
46. LESAFFER G, DE SMET R, LAMEIRE N, DHOND T, DUYM P, VANHOLDER R: Intra-dialytic removal of protein-bound uraemic toxins: Role of solute characteristics and of dialyzer membrane. *Nephrol Dial Transplant* 15:50-57, 2000
47. ANDERSTAM B, MAMOUEH AH, SÖDERSTEN P, BERGSTRÖM J: Middle-sized molecule fractions isolated from uremic ultrafiltrate and normal urine inhibit ingestive behavior in the rat. *J Am Soc Nephrol* 7:2453-2460, 1996
48. KAMANNA VS, KASHYAP ML, PAI R, BUI DT, JIN FY, ROH DD, SHAH GM, KIRSCHENBAUM MA: Uremic serum subfraction inhib-

- its apolipoprotein A-I production by a human hepatoma cell line. *J Am Soc Nephrol* 5:193-200, 1994
49. ANDRESS DL, HOWARD GA, BIRNBAUM RS: Identification of a low molecular weight inhibitor of osteoblast mitogenesis in uremic plasma. *Kidney Int* 39:942-945, 1991
 50. HORNBERGER JC, CHERNEW M, PETERSEN J, GARBER AM: A multivariate analysis of mortality and hospital admissions with high-flux dialysis. *J Am Soc Nephrol* 3:1227-1237, 1992
 51. HAKIM RM, HELD PJ, STANNARD DC, WOLFE RA, PORT FK, DAUGIRDAS JT, AGODOA L: Effect of the dialysis membrane on mortality of chronic hemodialysis patients. *Kidney Int* 50:566-570, 1996
 52. CHANDRAN PKG, LIGGETT R, KIRKPATRICK B: Patient survival on PAN/AN69 membrane hemodialysis: A ten year analysis. *Kidney Int* 43(Suppl 41):S287-S290, 1993
 53. KODA Y, NISHI S, MIYAZAKI S, HAGINOSHITA S, SAKURABAYASHI T, SUZUKI M, SAKAI S, YUASA Y, HIRASAWA Y, NISHI T: Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients. *Kidney Int* 52:1096-1101, 1997
 54. KABANDA A, JADOUL M, POCHE T JM, LAUWERYS R, VAN YPERSELE DE STRIHOUC, BERNARD A: Determinants of the serum concentrations of low molecular weight proteins in patients on maintenance hemodialysis. *Kidney Int* 45:1689-1696, 1994
 55. PELLEYMOUNTER MA, CULLEN MJ, BAKER MB, HECHT R, WINTERS D, BOONE T, COLLINS F: Effects of the obese gene produce on body weight regulation in ob/ob mice. *Science* 269:540-543, 1995
 56. HAALAS JL, GAJIWALA KS, MAFFEI M, COHEN SL, CHAIT BT, RABINOWITZ D, LALLONE RL, BURLEY SK, FRIEDMAN JM: Weight-reduction effects of the plasma protein encoded by the obese gene. *Science* 269:543-546, 1995
 57. SHARMA K, CONSIDINE RV, MICHAEL B, DUNN SR, WEISBERG LS, KURNIK BRC, KURNIK PB, O'CONNOR J, SINHA M, CARO JF: Plasma leptin is partly cleared by the kidney and is elevated in hemodialysis patients. *Kidney Int* 51:1980-1985, 1997
 58. HEIMBÜRGER O, LÖNNQVIST F, DANIELSSON A, NORDENSTRÖM J, STENVINKEL P: Serum immunoreactive leptin concentration and its relation to the body fat content in chronic renal failure. *J Am Soc Nephrol* 8:1423-1430, 1997
 59. COYNE DW, DAGOGO-JACK S, KLEIN S, MERABET E, AUDRAIN J, LANDT M: High-flux dialysis lowers plasma leptin concentration in chronic dialysis patients. *Am J Kidney Dis* 32:1031-1035, 1998
 60. BROWNLEE M, CERAMI A, VLASSARA H: Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. *N Engl J Med* 318:1315-1321, 1988
 61. PAPANASTASIOU P, GRASS L, RODELA H, PATRIKAREA A, OREOPOULOS D, DIAMANDIS EP: Immunological quantification of advanced glycosylation end-products in the serum of patients on hemodialysis or CAPD. *Kidney Int* 46:216-222, 1994
 62. IMANI F, HORII Y, SUTHANTHIRAN M, SKOLNIK EY, MAKITA Z, SHARMA V, SEHAJPAL P, VLASSARA H: Advanced glycosylation end product-specific receptors on human and rat T-lymphocytes mediate synthesis of interferon gamma: Role in tissue remodeling. *J Exp Med* 178:2165-2172, 1993
 63. MIYATA T, INAGI R, IIDA Y, SATO M, YAMADA N, ODA O, MAEDA K, SEO H: Involvement of β_2 -microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. *J Clin Invest* 93:521-528, 1994
 64. BUCALA R, TRACEY KJ, CERAMI A: Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. *J Clin Invest* 87:432-438, 1991
 65. WITKO-SARSAT V, FRIEDLANDER M, CAPELLÈRE-BLANDIN C, NGUYEN-KHOA T, NGUYEN AT, ZINGRAFF J, JUNGERS P, DESCAMPS-LATSCHA B: Advanced oxidation protein products as a novel marker of oxidative stress in uremia. *Kidney Int* 49:1304-1313, 1996
 66. MIYATA T, VAN YPERSELE DE STRIHOUC, KUROKAWA K, BAYNES JW: Alterations in nonenzymatic biochemistry in uremia: Origin and significance of "carbonyl stress" in long-term uremic complications. *Kidney Int* 55:389-399, 1999
 67. MAKITA Z, BUCALA R, RAYFIELD EJ, FRIEDMAN EA, KAUFMAN AM, KORBET SM, BARTH RH, WINSTON JA, FUH H, MANOGUE KR, CERAMI A, VLASSARA H: Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. *Lancet* 343:1519-1522, 1994
 68. MACLEISH KR, KLEIN JB, LEDERER ED, HEAD KZ, WARD RA: Azotemia, TNF α and LPS prime the human neutrophil oxidative burst by distinctive mechanisms. *Kidney Int* 50:407-416, 1996
 69. WOLFF SP, GARNER A, DEAN RT: Free radicals, lipids and protein degradation. *Trends Biochem Sci* 11:27-31, 1986
 70. MAGGI E, BELLAZZI R, FALASCHI F, FRATTONI A, PERANI G, FINARDI G, GAZO A, NAI M, ROMANINI D, BELLOMO G: Enhanced LDL oxidation in uremic patients: An additional mechanism for accelerated atheromatosis? *Kidney Int* 45:876-883, 1994
 71. ROSELAAR SE, NAZHAT NB, WINYARD PG, JONES P, CUNNINGHAM J, BLAKE DR: Detection of oxidants in uremic plasma by electron spin resonance spectroscopy. *Kidney Int* 48:199-206, 1995
 72. TATSUMI T, FLISS H: Hypochlorous acid and chloramines increase endothelial permeability: Possible role of cellular zinc. *Am J Physiol* 267:H1597-H1607, 1994
 73. BILZER M, LAUTERBURG BH: Effects of hypochlorous acid and chloramines on vascular resistance, cell integrity, and biliary glutathione disulfide in the perfused rat liver: Modulation by glutathione. *J Hepatol* 13:84-89, 1991
 74. HEGBRANT J, THYSELL H, EKMAN R: Elevated plasma levels of opioid peptides and delta sleep-inducing peptide but not of corticotropin-releasing hormone in patients receiving chronic hemodialysis. *Blood Purif* 9:188-194, 1991
 75. HÖRL WH, HAAG-WEBER M, GEORGOPOULOS A, BLOCK LH: Physicochemical characterization of a polypeptide present in uremic serum that inhibits the biological activity of polymorphonuclear cells. *Proc Natl Acad Sci USA* 87:6353-6357, 1990
 76. HAAG-WEBER M, MAI B, HÖRL WH: Isolation of a granulocyte inhibitory protein from uraemic patients with homology of β_2 -microglobulin. *Nephrol Dial Transplant* 9:382-388, 1994
 77. TSCHESCHE H, KOPP C, HÖRL WH, HEMPELMANN U: Inhibition of degradation of polymorphonuclear leukocytes by angiogenin and its tryptic fragment. *J Biol Chem* 269:30274-30280, 1994
 78. COHEN J, RUDNICKI M, HÖRL WH: Isolation of modified ubiquitin as a neutrophil chemotaxis inhibitor from uremic patients. *J Am Soc Nephrol* 9:451-456, 1998
 79. IKEDA U, KANBE T, SHIMADA K: Adrenomedullin increases inducible nitric oxide synthase in rat vascular smooth muscle cells stimulated with interleukin-1. *Hypertension* 27:1240-1244, 1996
 80. JADOUL M, GARBAR C, NOËL H, SENNESAE J, VANHOLDER R, BERNAERT P, RORIVE G, HANIQUE G, VAN YPERSELE DE STRIHOUC C: Histological prevalence of β_2 -microglobulin amyloidosis in hemodialysis: A prospective post-mortem study. *Kidney Int* 51:1928-1932, 1997
 81. JADOUL M, GARBAR C, VANHOLDER R, SENNESAE J, MICHEL C, NOËL H, VAN YPERSELE DE STRIHOUC C: Prevalence of histological β_2 -microglobulin amyloidosis in CAPD-patients: Comparison with HD patients. *Kidney Int* 54:956-959, 1998
 82. NIWA T, SATO M, KATSUZAKI T, TOMOO T, MIYAZAKI T, TATEMACHI N, TAKEI Y, KONDO T: Amyloid β_2 -microglobulin is modified with Nⁱ-(carboxymethyl) lysine in dialysis related amyloidosis. *Kidney Int* 50:1303-1309, 1996
 83. LEHNERT H, JACOB C, MARZOLL I, SCHMIDT-GAYK H, STEIN G, RITZ E: Prevalence of dialysis-related amyloidosis in diabetic patients: Diabetic Amyloid Study Group. *Nephrol Dial Transplant* 11:2004-2007, 1996
 84. CLARK WR, MACIAS WL, MOLITORIS BA, WANG NHL: Membrane adsorption of β_2 -microglobulin: Equilibrium and kinetic characterization. *Kidney Int* 46:1140-1146, 1994
 85. VAN YPERSELE DE STRIHOUC C, JADOUL M, MALGHEM J, MALDAGUE B, JAMART J: Effect of dialysis membrane and patient's age on signs of dialysis-related amyloidosis. *Kidney Int* 39:1012-1019, 1991
 86. PASCUAL M, SCHIFFERLI JZ: Adsorption of complement factor D by polyacrylonitrile dialysis membranes. *Kidney Int* 43:903-911, 1992
 87. PASCUAL M, STEIGER G, ESTREICHER J, MACON K, VOLANAKIS JE, SCHIFFERLI JA: Metabolism of complement factor D in renal failure. *Kidney Int* 34:529-536, 1988
 88. VOLANAKIS JE, BARNUM SR, GIDDENS M, GALLA JH: Renal filtra-

- tion and catabolism of complement protein D. *N Engl J Med* 312:395-399, 1985
89. STURFELT G, TRUEDSSON L, SJOHOLM A: Complement factor D in uremia. (letter) *N Engl J Med* 312:1577, 1985
 90. AMANN K, WIEST G, MALL G, RITZ E, KLAUS G: A role of parathyroid hormone for the activation of cardiac fibroblasts in uremia. *J Am Soc Nephrol* 4:1814-1819, 1994
 91. RAO DS, SHIH M, MOHINI R: Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. *N Engl J Med* 328:171-175, 1993
 92. MASSRY SG, SMOGORZEWSKI M: Mechanisms through which parathyroid hormone mediates its deleterious effects on organ function in uremia. *Semin Nephrol* 14:219-231, 1994
 93. MASSRY SG, SMOGORZEWSKI M: Parathyroid hormone, chronic renal failure and the liver. *Kidney Int* 52(Suppl 62):S5-S7, 1997
 94. SMOGORZEWSKI M, MASSRY SG: Uremic cardiomyopathy: Role of parathyroid hormone. *Kidney Int* 52(Suppl 62):S12-S14, 1997
 95. D'AMOUR P, JOBIN J, HAMEL LL, 'ECUYER N: iPTH values during hemodialysis: Role of ionized Ca, dialysis membranes and iPTH assays. *Kidney Int* 38:308-314, 1990
 96. WALSER M, HILL SB: Free and protein-bound tryptophan in serum of untreated patients with chronic renal failure. *Kidney Int* 44:1366-1371, 1993
 97. EFIMOV S, SHEVCHENKO V, SHCHUKIN I, PREOBRAZHENSKAYA M: The influence of 1'-methyl- and 1'-ethylascorbinogen on metabolism of arachidonic acid in murine spleen cells. *Biochem Biophys Res Commun* 190:895-900, 1993
 98. DEPNER TA: Suppression of tubular anion transport by an inhibitor of serum protein binding in uremia. *Kidney Int* 20:511-518, 1981
 99. MABUCHI H, NAKAHASHI H: Inhibition of hepatic glutathione S-transferases by a major endogenous ligand substance present in uremic serum. *Nephron* 49:281-286, 1988
 100. LIM CF, BERNARD BF, DE JONG M, DOCTER R, KRENNING EP, HENNEMANN G: A furan fatty acid and indoxyl sulfate are the putative inhibitors of thyroxine hepatocyte transport in uremia. *J Clin Endocrinol Metab* 76:318-324, 1993
 101. NIWA T, AIUCHI T, NAKAYA K, EMOTO Y, MIYAZAKI T, MAEDA K: Inhibition of mitochondrial respiration by furancarboxylic acid accumulated in uremic serum in its albumin-bound and non-dialyzable form. *Clin Nephrol* 39:92-96, 1993
 102. NIWA T, ASADA H, TSUTSUI S, MIYAZAKI T: Efficient removal of albumin-bound furancarboxylic acid by protein-leaking hemodialysis. *Am J Nephrol* 15:463-467, 1995
 103. SHINZATO T, MORITA H, MAEDA K: Metabolism and kinetics of propylurofuranic acid in end-stage renal failure. *ASAIO J* 40:94-96, 1994
 104. COSTIGAN MG, YACOOB M, LINDUP WE: Effects of haemodialysis and continuous ambulatory peritoneal dialysis on the plasma clearance of an albumin-bound furan dicarboxylic acid. *Nephrol Dial Transplant* 10:648-652, 1995
 105. CARLISLE EJJ, DONNELLY SM, VASUVATTAKUL S, KAMEL KS, TOBE S, HALPERIN ML: Glue sniffing and distal renal tubular acidosis: Sticking to the facts. *J Am Soc Nephrol* 1:1019-1027, 1991
 106. VANHOLDER R, VAN LANDSCHOOT N, DE SMET R, SCHOOTS A, RINGOIR S: Drug protein binding in chronic renal failure: Evaluation of nine drugs. *Kidney Int* 33:996-1004, 1988
 107. VANHOLDER R, HOEFFLIGER N, DE SMET R, RINGOIR S: Extraction of protein bound ligands from azotemic sera: Comparison of 12 deproteinization methods. *Kidney Int* 41:1707-1712, 1992
 108. SPUSTOVA V, CERNAY P, GOLIER I: Inhibition of glucose utilization in uremia by hippurate: Liquid chromatographic isolation and mass spectrometric and nuclear magnetic resonance spectroscopic identification. *J Chromatogr* 490:186-192, 1989
 109. ZIMMERMAN L, JÖRNVALL H, BERGSTRÖM J: Phenylacetylglutamine and hippuric acid in uremic and healthy subjects. *Nephron* 55:265-271, 1990
 110. VANHOLDER R, DE SMET R, SCHOOTS A, RINGOIR S: Correlation of a colorimetric and a HPLC method for the determination of hippuric acid concentrations in uremia. *Nephron* 49:164-168, 1988
 111. PERNA AF, INGROSSO D, DE SANTO NG, GALLETTI P, ZAPPIA V: Mechanism of erythrocyte accumulation of methylation inhibitor S-adenosylhomocysteine in uremia. *Kidney Int* 47:247-253, 1995
 112. CLARKE R, DALY L, ROBINSON K, NAUGHTEN E, CAHALANE S, FOWLER B, GRAHAM I: Hyperhomocysteinemia: An independent risk factor for vascular disease. *N Engl J Med* 324:1149-1155, 1991
 113. BOUSHEY CJ, BERESFORD SAA, OMENN GS, MOTULSKY AG: A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. *JAMA* 274:1049-1057, 1995
 114. HULTBERG B, ANDERSSON A, STERNER G: Plasma homocysteine in renal failure. *Clin Nephrol* 40:230-234, 1993
 115. BOSTOM AG, SHEMIN D, LAPANE KL, NADEAU MR, SUTHERLAND P, CHAN J, ROZEN R, YOBURN D, JACQUES PF, SELHUB J, ROSENBERG IH: Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patients. *Atherosclerosis* 123:193-202, 1996
 116. FÖDINGER M, MANNHALTER C, WÖFL G, PABINGER I, MÜLLER E, SCHMID R, HÖRL W, SUNDER-PLOSSMANN G: Mutation (677 C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients. *Kidney Int* 52:517-523, 1997
 117. PERNA AF, INGROSSO D, GALLETTI P, ZAPPIA V, DE SANTO NG: Membrane protein damage and methylation reactions in chronic renal failure. *Kidney Int* 50:358-366, 1996
 118. TSAI C, PERRELLA MA, YOSHIZUMI M, HSIEN CM, HABA E, SCHLAGEL R, LEE ME: Promotion of vascular smooth muscle cell growth by homocysteine: A link to atherosclerosis. *Proc Natl Acad Sci USA* 91:10193-10197, 1992
 119. HARPEL PC, ZHANG X, BORTH W: Homocysteine and hemostasis: Pathogenetic mechanisms predisposing to thrombosis. *J Nutr* 126:1285S-1289S, 1996
 120. UBBINK JB, VERMAAK WJH, VAN DER MERWE A, BECKER PJ: Vitamin B-12, vitamin B-6, and folate nutritional status in men with hyperhomocysteinemia. *Am J Clin Nutr* 57:47-53, 1993
 121. BOSTOM AG, GOHH RY, BEAULIEU AJ, NADEAU MR, HUME AL, JACQUES PF, SELHUB J, ROSENBERG IH: Treatment of hyperhomocysteinemia in renal transplant recipients: A randomized, placebo-controlled trial. *Ann Intern Med* 127:1089-1092, 1997
 122. WILCKEN DEL, DUDMAN NPB, TYRRELL PA, ROBERTSON MR: Folic acid lowers elevated plasma homocysteine in chronic renal insufficiency: Possible implications for prevention of vascular disease. *Metabolism* 37:697-701, 1988
 123. SORIA C, CHADEFaux B, COUDE M, GAILLARD O, KAMOUN P: Concentrations of total homocysteine in plasma in chronic renal failure. *Clin Chem* 36:2137-2138, 1990
 124. NIWA T, ISE M: Indoxyl sulfate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis. *J Lab Clin Med* 124:96-104, 1994
 125. DE SMET R, GLORIEUX G, VANHOLDER R: P-cresol and uric acid: Two old uremic toxins revisited. *Kidney Int* 52(Suppl 62):S8-S11, 1997
 126. ANDERSON IB, MULLEM WH, MEEKER JE, KHOJASTEH-BAKHT SC, OISHI S, NELSON SD, BLANC PD: Pennyroyal toxicity: Measurement of toxic metabolite levels in two cases and review of the literature. *Ann Intern Med* 124:726-734, 1996
 127. THOMPSON DC, PERERA K, FISHER R, BRENDEN K: Cresol isomers: Comparison of toxic potency in rat liver slices. *Toxicol Appl Pharmacol* 125:51-58, 1994
 128. VANHOLDER R, DE SMET R, WATERLOOS MA, VAN LANDSCHOOT N, VOGEELEERE P, HOSTE E, RINGOIR S: Mechanisms of the uremic inhibition of phagocyte reactive species production: Characterization of the role of p-cresol. *Kidney Int* 47:510-517, 1995
 129. ABREO K, SELLA M, GAUTREAU S, DE SMET R, VOGEELEERE P, RINGOIR S, VANHOLDER R: P-cresol and phenol increase the uptake and toxicity of aluminum in cultured mouse hepatocytes. *J Am Soc Nephrol* 8:935-942, 1997
 130. NIWA T, ISE M, MIYAZAKI T, MEADA K: Suppressive effect of an oral sorbent on the accumulation of p-cresol in the serum of experimental uremic rats. *Nephron* 65:82-87, 1993
 131. NIWA T: Phenol and p-cresol accumulated in uremic serum measured by HPLC with fluorescence detection. *Clin Chem* 39:108-111, 1993
 132. KUSHNER D, BECKMAN B, NGUYEN L, CHEN S, DELLA SANTINA C, HUSSERL F, RICE J, FISHER JW: Polyamines in the anemia of end-stage renal disease. *Kidney Int* 39:725-732, 1991

133. ROCK DM, MACDONALD RL: Spermine and related polyamines produce a voltage-dependent reduction of N-methyl-D-aspartate receptor single-channel conductance. *Mol Pharmacol* 42:157-164, 1992
134. LENZEN S, RUSTENBECK I: Effects of IP₃, spermine, and Mg²⁺ on regulation of Ca²⁺ transport by endoplasmic reticulum and mitochondria in permeabilized pancreatic islets. *Diabetes* 40:323-326, 1991
135. SZABO C, SOUTHAN GJ, WOOD E, THIEMERMANN C, VANE JR: Inhibition by spermine of the induction of nitric oxide synthase in J774.2 macrophages: Requirement of a serum factor. *Br J Pharmacol* 112:355-356, 1994
136. HELD PJ, PORT FK, WOLFE RA, STANNARD DC, CARROLL C, DAUGIRDAS JT, BLOEMBERGEN W, GREER J, HAKIM RM: The dose of hemodialysis and patient mortality. *Kidney Int* 50:550-556, 1996
137. GOTCH F, SARGENT JA: A mechanistic analysis of the National Cooperative Dialysis Study. *Kidney Int* 28:526-534, 1985
138. MAHIOUT A, HEINHOLD H, KESSEL M, SCHULZE H, BAURMEISTER U: Dialyzer membranes: Effect of surface area and chemical modification of cellulose on complement and platelet activation. *Artif Organs* 11:149-154, 1987
139. LEYPOLDT JK, CHEUNG AK, CARROLL C, STANNARD DC, PEREIRA BJG, AGODOA L, PORT FK: Effect of dialysis membranes and middle molecule removal on chronic hemodialysis patient survival. *Am J Kidney Dis* 33:349-355, 1999
140. STANGE J, RAMLOW W, MITZNER S, SCHMIDT R, KLINKMANN H: Dialysis against a recycled albumin solution enables removal of albumin-bound toxins. *Artif Organs* 17:809-813, 1993
141. KESHAVIAH P, NOLPH KD, VAN STONE J: The peak concentration hypothesis: A urea kinetic approach to comparing the adequacy of continuous ambulatory peritoneal dialysis and hemodialysis. *Perit Dial Int* 9:257-260, 1989
142. CHEN TW, HUANG TP, LIU MC, WANG ML: The removal index for evaluation of dialysis. *Perit Dial Int* 16:128-134, 1996
143. BABB A, STRAND M, UVELLI D: Quantitative description of dialysis treatment: A dialysis index. *Kidney Int* 7:S23-S29, 1975
144. KESHAVIAH P: Adequacy of CAPD: A quantitative approach. *Kidney Int* 38:S160-S164, 1992
145. FENTON SS, SCHAUBEL DE, DESMEULES M, MORRISON HI, MAO Y, COPLESTON P, JEFFERY JR, KJELLSTRAND CM: Hemodialysis versus peritoneal dialysis: A comparison of adjusted mortality rates. *Am J Kidney Dis* 30:334-342, 1997
146. VAN BIESEN W, VANHOLDER R, VEYS N, DHONDT A, LAMEIRE N: An evaluation of an integrative care approach for ESRD patients. *J Am Soc Nephrol* 11:116-125, 2000
147. CANADA USA (CANUSA) PERITONEAL DIALYSIS STUDY GROUP: Adequacy of dialysis and nutrition in continuous peritoneal dialysis: Association with clinical outcomes. *J Am Soc Nephrol* 7:198-207, 1996
148. NIWA T, YAZAWA T, KODAMA T, UEHARA Y, MAEDA K, YAMADA K: Efficient removal of albumin-bound furancarboxylic acid, an inhibitor of erythropoiesis, by continuous ambulatory peritoneal dialysis. *Nephron* 56:241-245, 1990
149. MOTOJIMA M, NISHIJIMA F, IKOMA M, KAWAMURA T, YOSHIOKA T, FOGO AB, SAKAI T, ICHIKAWA I: Role for "uremic toxin" in the progressive loss of intact nephrons in chronic renal failure. *Kidney Int* 40:461-469, 1991
150. NIWA T, ISE M, MIYAZAKI T: Progression of glomerular sclerosis in experimental uremic rats by administration of indole, a precursor of indoxyl sulfate. *Am J Nephrol* 14:207-212, 1994
151. CHANDRA M, CLEMONS G, McVICAR M, WILKES B, BLUESTONE P, MAILLOUX L, MOSSEY R: Serum erythropoietin levels and hematocrit in end stage renal disease: Influence of the mode of dialysis. *Am J Kidney Dis* 12:208-213, 1988
152. DE PAEPE M, SCHELSTRAETE K, RINGOIR S, LAMEIRE N: Influence of continuous ambulatory peritoneal dialysis on the anemia of end stage renal disease. *Kidney Int* 23:744-748, 1983
153. KUSHNER D, BECKMAN B, FISHER JW: Do polyamines play a role in the pathogenesis of the anemia of end stage renal disease? *Kidney Int* 36:171-174, 1989
154. HIDA M, AIBA Y, SAWAMURA S, SUZUKI N, SATOH T, KOGA Y: Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oral administration of Lebenin[®], a lactic acid bacteria preparation, to uremic patients undergoing hemodialysis. *Nephron* 74:349-355, 1996
155. LING WH, HÄNNINEN O: Shifting from a conventional diet to an uncooked vegan diet reversibly alters fecal hydrolytic activities in humans. *J Nutr* 122:924-930, 1992
156. NIWA T, YAZAWA T, ISE M, SUGANO M, KODAMA T, UEHARA Y, MAEDA K: Inhibitory effect of oral sorbent on accumulation of albumin-bound indoxyl sulfate in serum of experimental uremic rats. *Nephron* 57:84-88, 1991
157. NIWA T, MIYAZAKI T, HASHIMOTO N, HAYASHI H, ISE M, UEHARA Y, MAEDA K: Suppressed serum and urine levels of indoxyl sulfate by oral sorbent in experimental uremic rats. *Am J Nephrol* 12:201-206, 1992
158. URENA P, KUBRUSLY M, MANNSTADT M, HRUBY M, TRINH TRANG TAN MM, SILVE C, LACOUR B, ABOU-SAMRA AB, SEGRE GV, DRÜEKE T: The renal PTH/PTHrP receptor is down-regulated in rats with chronic renal failure. *Kidney Int* 45:605-611, 1994
159. SMOGORZEWSKI M, TIAN J, MASSRY SG: Down-regulation of PTH-PTHrP receptor of heart in CRF: Role of [Ca²⁺]. *Kidney Int* 47:1182-1186, 1995
160. DHONDT AM, VANHOLDER RC, RINGOIR S: Angiotensin-converting enzyme inhibitors and higher erythropoietin requirement in chronic hemodialysis patients. *Nephrol Dial Transplant* 10:2107-2109, 1995
161. YOKOZAWA T, FUJIOKA K, OURA H, NONAKA G, NISHIOKA I: Effects of rhubarb tannins on uremic toxins. *Nephron* 58:155-160, 1991
162. YATZIDIS H, HOUTSICOS D, AGROYANNIS B, PAPASTEPHANIDIS C, FRANCOSPLEMENOS M, DELATOL AZ: Biotin in management of uremic neurologic disorders. *Nephron* 36:183-186, 1984
163. BOSTOM AG, SHEMIN D, LAPANE KL, HUME AL, YOBURN D, NADEAU MR, BENDICH A, SELHUB J, ROSENBERG IH: High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients. *Kidney Int* 49:147-152, 1996